安旭生物(688075) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥121,477,537.33, representing a decrease of 97.78% compared to the same period last year[3] - The net profit attributable to shareholders was ¥50,831,559.77, down 98.10% year-over-year[3] - The net profit after deducting non-recurring gains and losses was ¥8,359,409.24, reflecting a decline of 99.69% compared to the previous year[3] - Basic and diluted earnings per share were both ¥0.56, down 98.10% from the same period last year[3] - Total operating revenue for Q1 2023 was ¥121,477,537.33, a significant decrease from ¥5,474,543,757.08 in Q1 2022[19] - Net profit for Q1 2023 was ¥50,378,384.59, compared to ¥2,681,700,014.97 in Q1 2022, indicating a substantial decline[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.56, a sharp drop from ¥29.54 in Q1 2022[21] Cash Flow - The net cash flow from operating activities was -¥119,997,845.24, a decrease of 103.30% year-over-year[3] - In Q1 2023, the net cash flow from operating activities was -119,997,845.24, a significant decrease compared to 3,631,925,330.95 in Q1 2022[24] - Total cash inflow from operating activities was 306,265,340.17, down from 4,867,104,534.58 in the same period last year[24] - Cash outflow from operating activities reached 426,263,185.41, compared to 1,235,179,203.63 in Q1 2022[24] - The net cash flow from investment activities was -1,219,506,435.64, an improvement from -3,762,403,576.95 in Q1 2022[25] - Cash inflow from investment activities totaled 3,441,647,758.17, up from 239,645,141.51 in the previous year[25] - Cash outflow from investment activities was 4,661,154,193.81, compared to 4,002,048,718.46 in Q1 2022[25] - The net cash flow from financing activities was -11,506.16, compared to -2,480,000.00 in Q1 2022[26] - The ending cash and cash equivalents balance was 794,525,554.37, down from 1,907,634,230.41 at the end of Q1 2022[26] - The company reported a significant decrease in cash received from operating activities, with a drop of approximately 93.7% year-over-year[24] - The company experienced a cash outflow of 1,343,634,889.25 in Q1 2023, compared to a smaller outflow of 139,575,147.11 in Q1 2022[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,943,063,580.71, a slight increase of 0.02% from the end of the previous year[4] - Total current assets as of March 31, 2023, amounted to ¥6,248,634,020.11, a slight increase from ¥6,206,106,624.28 at the end of 2022[15] - Total liabilities for Q1 2023 were ¥1,451,715,121.80, down from ¥1,522,910,864.17 in the previous period[17] - The company's total equity as of Q1 2023 was ¥5,491,348,458.90, compared to ¥5,418,771,342.16 previously[17] Research and Development - Total R&D investment amounted to ¥23,771,592.09, a decrease of 95.72% compared to the previous year[3] - The proportion of R&D investment to operating revenue increased by 9.43 percentage points to 19.57%[3] - Research and development expenses for Q1 2023 were ¥23,771,592.09, significantly lower than ¥555,198,928.03 in Q1 2022[20] Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,831[11] - The top ten shareholders collectively hold 59.79% of the company's shares, with the largest shareholder, Hangzhou Aixi Holdings, owning 26.87%[11] - The company distributed a cash dividend of ¥3.88 per share, with a capital reserve increase of 0.48 shares for every share held[12] Other Information - The company has engaged in securities lending, with a total of 106,100 shares lent out, leaving 801,637 shares held as restricted stock[12] - The company is focused on expanding its market presence and developing new technologies, although specific details were not disclosed in the report[13] - Other comprehensive income after tax for Q1 2023 was ¥8,357,524.90, compared to ¥2,589,324.05 in Q1 2022[21] - The company reported an investment income of ¥42,938,603.12 for Q1 2023, a notable increase from ¥137,100.00 in the previous period[20]